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A B S T R A C T
Objective: A multisite investigation compared the analytical performance of a point-of-care (POC) HbA1c device
with multiple commonly used HbA1c laboratory methods and an NGSP (National Glycohemoglobin
Standardization Program) reference method.
Research Design and Methods: The Afinion AS100 POC device analyzed HbA1c using 618 EDTA whole blood
excess patient specimens with clinically indicated HbA1c testing. Results were compared to measurements across
five clinical laboratories and the NGSP reference method. Precision was evaluated over 8–10 consecutive days
for low-, mid-, and high-range HbA1c specimens at all five sites.
Results: Over a wide range of HbA1c values (4.0%–15% HbA1c), 97.1% of the POC results and 94.5% of
routine laboratory results fell within the target value of± 6% of the NGSP reference method results. The POC
HbA1c results at 6.5% exhibited a total relative bias of −0.6% (−0.04% HbA1c) compared to the reference
method while the aggregate of laboratory methods displayed a relative bias of −0.9% (−0.06% HbA1c). The
total imprecision of the POC results ranged from 0.74–2.13% CV across the analytic measurement range com-
pared to 0.81–3.23% CV for the routine laboratory methods.
Conclusions: The accuracy and precision of the Afinion POC HbA1c method was comparable to the laboratory
HbA1c methods supporting the FDA's recent approval of the Afinion HbA1c Dx device for use in the diagnosis of
diabetes.
1. Introduction
Diabetes is a significant global public health concern, with an esti-
mated mortality rate of over 1.5 million lives per year [1]. Diabetes is a
chronic condition that results from autoimmune related insulin defi-
ciency (type 1) or insulin resistance/β-cell dysfunction (type 2), with
type 2 diabetes comprising a majority of diabetes cases and new diag-
noses. Type 2 diabetes results from chronic hyperglycemia that leads to
insulin insensitivity at the cellular level and ultimately the inability to
adequately metabolize dietary glucose [1,2].
Hemoglobin A1c (HbA1c) is formed via non-enzymatic glycation on
the terminal valine of the β-globin chain. The concentration of HbA1c is
highly dependent upon the average lifespan of the red blood cell and
blood glucose concentrations, but is representative of an individual's
average blood glucose concentration over the last 2–3months [3,4].
Therefore, monitoring HbA1c concentrations are beneficial for asses-
sing long-term glycemic control. Clinical guidelines from the American
Diabetes Association, World Health Organization, and the International
Diabetes Federation recommend that a HbA1c cutoff≥6.5% (48mmol/
mol) can be utilized for the diagnosis of diabetes, if testing is conducted
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using an assay which is standardized and certified by the National
Glycohemoglobin Standardization Program (NGSP) and traceable to the
Diabetes Control and Complications Trial (DCCT) reference method
[1,2,5]. Recently, the FDA has cleared the Abbott (formerly Alere)
Afinion AS100 HbA1c Dx device as a moderately complex test for use in
the diagnosis of diabetes, which is a first for a point-of-care (POC)
HbA1c method.
Historically HbA1c point-of-care (POC) devices demonstrated sig-
nificant bias and variability when compared to non-POC assays, which
led to clinical guideline recommendations against utilization for diag-
nostic purposes [6–9]. However, there have been improvements in
HbA1c assays and technologies over time and further investigation into
the accuracy and precision of these devices is required. POC HbA1c
measurements could expedite diagnostic decisions and medical inter-
ventions provided they meet performance standards [6]. The purpose of
this multicenter study was to evaluate the analytical performance of
HbA1c using the Afinion AS100 POC analyzer between multiple sites,
and compare the performance characteristics to other frequently used
automated HbA1c assays and an NGSP reference method.
2. Materials and methods
2.1. Instrumentation
The analytical performance of the Afinion AS100 POC analyzer
(Alere Technologies AS) was compared to three clinical laboratory
HbA1c platforms (Roche Tina-quant® HbA1c Gen. 3, Bio-Rad Variant II
Turbo, Siemens Dimension Vista) across five clinical laboratories, and
with an NGSP reference laboratory (Secondary Reference Laboratory
#9, Tosoh G8 automated glycohemoglobin analyzer) (Table 1). The
Afinion AS100 is a POC instrument that quantifies HbA1c in capillary or
venous blood using boronate affinity methodology, which is highly
specific for 1,2-cis diols to measure total glycohemoglobin that is then
converted and reported as HbA1c. A single lot of test cartridges and
control materials was used for the study. The Roche Tina-quant® HbA1c
Gen. 3, used at two sites, and the Siemens Dimension Vista® HbA1c,
used at one site, are both turbidimetric inhibition immunoassays
(TINIA). The Bio-Rad Variant II Turbo, used at two sites, employs cation
exchange HPLC for direct measurement of HbA1c. The Roche and Bio-
Rad HbA1c assays are FDA-cleared for use as an aid in the diagnosis of
diabetes. The HbA1c reference method procedure (RMP) was per-
formed at the Diagnostic Diabetes Laboratory (DDL) in Columbia, MO
on the Tosoh G8 automated glycohemoglobin analyzer, which measures
HbA1c by cation exchange HPLC. The Tosoh G8 in the DDL is part of
the NGSP network.
If the POC HbA1c values differed by> 10% from the reference
method, specimens were reflexed for confirmatory testing at the DDL
using alternative NGSP certified boronate affinity methods (Ultra2 and
Premier Hb9210 HbA1c Analyzers, Trinity Biotech).
2.2. Study design
De-identified, remnant EDTA anti-coagulated whole blood speci-
mens with clinical orders and indications for HbA1c testing were uti-
lized for this study. The study began in June 2016 and completed in
June 2017. Each institution involved had the protocol reviewed and
approved by its local Institutional Review Board (IRB) before partici-
pation in the study was allowed. HbA1c was analyzed using the local
laboratory methods and the POC device at all five clinical sites.
Specimens were refrigerated after the initial laboratory measurement
and analyzed using the POC instrument within 72 h after collection.
Specimens were excluded from POC and routine laboratory measure-
ments if they were previously frozen or were known to have>5%
Hemoglobin F (HbF) present. After routine laboratory and POC mea-
surements were performed, aliquots of each sample were frozen within
72 h of initial collection and stored at≤−70 °C prior to shipping to the
NGSP reference laboratory for analysis.
The accuracy of the Afinion HbA1c Dx test was assessed at each site
by evaluating a minimum of 120 specimens evenly distributed across
the low (4.00–6.00% HbA1c), mid (6.01–7.00% HbA1c) and high
(7.01–15.00% HbA1c) range for HbA1c. Results were compared to
routine clinical laboratory methods and to the NGSP reference method.
Precision of the POC device relative to each laboratory method was
conducted and evaluated independently at each site using three EDTA
whole blood specimens (one specimen at each target HbA1c value).
Each site independently created their own pools for low, medium, and
high HbA1c at similar nominal concentrations. Each specimen was
analyzed in duplicate in the morning and again in the afternoon, for a
total of 4 measurements per day by each laboratory's and POC methods
over 8–10 consecutive days.
3. Results
3.1. Accuracy of POC and laboratory HbA1c values to RMP
A total of 618 patient specimens were analyzed between the POC
and all laboratory methods. The Deming regression demonstrated a
strong correlation (Pearson R=0.994) between the Afinion HbA1c
values and the Tosoh G8 reference method values (Fig. 1A). The mean
of laboratory sites HbA1c also displayed a strong correlation (Pearson
R=0.989) with the reference method values (Fig. 1B).
Table 2 shows the total biases of the AS100 results, the aggregate
mean of all local laboratory method results, and individual laboratory
method results at 5%, 6.5%, and 8% HbA1c compared to the reference
method (SRL#9-Tosoh G8). The current NGSP requirement for total
allowable error (TAE) is± 6% across the measurement range manu-
facturer certification requires that 37/40 (92.5%) of results must be
within± 6% of the SRL [10]. 600 of 618 POC results (97.1%) and 584
of 618 laboratory results (94.5%) were within±6% TAE when com-
pared to the reference method. Within the mid-range (6.01–7.00%
HbA1c) of HbA1c and near the diagnostic decision point (6.5% HbA1c),
Table 1
Local laboratory methods of participating clinical laboratories.
Site Clinical laboratory Laboratory method Test principle
1 University of California, San Diego (UCSD) Roche Tina-quant® HbA1c Gen. 3⁎ Turbidimetric inhibition immunoassay
2 Washington University (WashU)
3 University of Minnesota (UMN) Siemens Dimension Vista
4 University of California, San Francisco (UCSF) Bio-Rad Variant II Turbo HbA1c⁎ Cation-exchange HPLC
5 Hennepin Country Medical Center/Minneapolis Medical Research
Foundation (MMRF)
N/A Diabetes Diagnostic Laboratory (Columbia, MO) Tosoh G8 Automated Glycohemoglobin Analyzer⁎,a
Ultra2⁎ and Premier Hb9210⁎,a Boronate Affinity
⁎ FDA cleared for diagnosis.
a NGSP certified reference method.
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Fig. 1. Accuracy-weighted Deming regression plots for (a) POC and (b) routine laboratory standard-of-care (SOC) methods compared to the NGSP reference method
(Tosoh G8).
Table 2
Accuracy-weighted Deming regression results compared to the NGSP reference method. Units are meant to indicate a relative % of the measured value. 95%
Confidence intervals are shown in [ ].
Afinion AS100 Aggregate mean of laboratory
methods
Tina Quant Gen.3 Variant II turbo Dimension vista
Count 618 618 247 241 130
Intercept −0.06 [−0.14,0.02] −0.06 [−0.14,0.03] −0.15 [−0.29, −0.01] −0.05 [−0.19,0.1] 0.19 [0.03,0.35]
Slope 1.003 [−0.99,1.02] 1.000 [0.99,1.01] 1.008 [0.99,1.03] 1.002 [0.98,1.03] 0.969 [0.94,0.99]
Pearson R 0.994 0.989 0.993 0.984 0.994
Bias at 5% HbA1c −0.9% [−1.38%,
−0.45%]
−1.1% [−1.61%, −0.65%] −2.3% [−3.1%, −1.4%] −0.8% [−1.36%, −0.19%] −0.7% [−0.21%,1.63%]
Bias at 6.5% HbA1c −0.6% [−0.86%,
−0.39%]
−0.9% [−1.18%, −0.58%] −1.6% [−1.97%,
−1.14%]
−0.5% [−1.26%,0.46%] −0.2% [−1.35%, −0.08%]
Bias at 8% HbA1c −0.5% [−0.76%,
−0.15%]
−0.7% [−1.13%, −0.31%] −1.1% [−1.61%,
−0.62%]
−0.4% [−1.26%,0.46%] −0.7% [−1.35%, −0.08%]
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193 of 200 POC values (96.5%) and 190 of 200 laboratory values
(95.0%) were within± 6% TAE limits. Absolute bias of the 7 POC re-
sults in the mid-range that had a relative bias> 6% ranged from
−0.58% HbA1c to +0.46% HbA1c when compared to target reference
values. Absolute bias of the 10 laboratory HbA1c results in the mid-
range that had a relative bias> 6% ranged from −0.6% to +0.6%
when compared to the target reference values.
Difference plots comparing the HbA1c results of the POC and rou-
tine laboratory methods to the average of duplicate HbA1c values
analyzed at the NGSP reference laboratory are displayed in Fig. 2. Both
plots indicate minimal proportional and constant error for both the POC
and routine laboratory methods in comparison to the reference method.
At the HbA1c diagnostic decision point of 6.5%, the POC results ex-
hibited a total bias of −0.6% (e.g. an absolute bias of −0.04%HbA1c)
compared to the reference method while the aggregate of laboratory
methods displayed a total bias of −0.9% (e.g. an absolute bias of
−0.06%HbA1c).
3.2. Precision
Table 3 displays the total imprecision (%CV) of the POC device over
8–10 days for low-, mid-, and high-range specimens (mean HbA1c
values= 5.3%, 6.5%, 9.8%, respectively) with %CVs of 1.46%, 1.35%,
and 0.85% respectively with data combined between all five sites, and
varied from 0.97% to 1.85% at individual sites. The Roche mean HbA1c
values were 5.2%, 6.6%, and 9.2% with calculated %CVs of 1.89%,
1.28%, and 1.55%, respectively, when combined across the two la-
boratories using the Roche method. The BioRad mean HbA1c values
were 5.4%, 6.6%, and 11.5% with calculated %CVs of 2.39%, 1.87%,
and 0.83%, respectively, across the two BioRad sites. The Siemens
method, used at one site, had mean HbA1c values of 5.1%, 6.7%, and
8.5% with %CVs of 3.23%, 1.96%, and 1.44%, respectively.
4. Discussion
This multicenter analytical trial demonstrates equivalent or superior
performance of the Alere Afinion POC HbA1c device compared to
routine clinical laboratory HbA1c assays currently employed in the
diagnosis of diabetes. These results are specific to the Afinion POC
HbA1c method when performed in a laboratory setting and are in ac-
cordance with previously published results [11]. The Afinion device
had stronger linear correlation (Pearson R) than the aggregate of la-
boratory methods with less bias and improved precision across the
analytical measurement range, further strengthening the potential uti-
lity of the Afinion AS100 for diagnosis and monitoring of diabetes.
Three specimens tested by the POC device (Fig. 2A) had HbA1c
results (mean A1c of 4.4%, 8.6% and 13.4%) that differed by>10%
relative to the NGSP reference method (mean A1c of 3.9%, 7.4%, and
11.6%). Repeat analysis of these specimens using an NGSP certified
boronate affinity method yielded results that were in close agreement
(within 3%, e.g. 0.3% HbA1c at an HbA1c of 8.6%) compared to the
POC HbA1c results. These results suggest that the discrepancies in
HbA1c values between POC and the reference measurements in these
three outliers were likely due to differences in methodologies as the two
methods based on boronate gave near identical results. For these three
specimens the differences in results appears to be due to differences
between boronate affinity and the direct measurement of HbA1c via
ion-exchange chromatography, and is not specific to the POC method.
Due to challenges in obtaining a fasting plasma glucose in some
patients, an FDA cleared POC HbA1c device that demonstrates com-
parable accuracy and precision to common laboratory platforms with
claims for diagnosis of diabetes has considerable clinical utility. The
ability to provide rapid, accurate HbA1c results to at-risk populations
using a POC device has the potential to further enable clinicians and
caregivers to appropriately diagnose, monitor and implement effective
therapies in patients with diabetes and reduce the risk of loss to follow-
up care.
In summary, the data here demonstrates that the analytical per-
formance of the Afinion POC HbA1c device is equivalent to a variety of
common laboratory methods across multiple laboratories. These data
support the recent FDA decision clearing the Afinion HbA1c Dx device
as substantially equivalent to routine clinical laboratory methods al-
lowing it to be used in the diagnosis of diabetes.
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